ADGM Overview

Insider Purchase at Scholar Rock: Srinivas Akkaraju bought 29,599 shares of Scholar Rock Holding (SRRK) for $1.18M at $39.92 each, seeing a 13.5% gain during the trading session.

Previous Investment by Akkaraju: Prior to this purchase, Akkaraju had acquired $18.81M worth of shares at $37.58 each within the last year.

Adagio Medical Holdings CEO Purchase: Todd Usen, CEO of Adagio Medical Holdings, purchased 207,315 shares for $225,973 at $1.09 each, while the stock was down about 2.5% on the day.

Market Performance: Scholar Rock Holding's stock was up approximately 0.4% on Wednesday, with SRRK reaching a high of $45.32 during trading.

B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.

Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.

Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.

Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.

Study Results: Adagio Medical's FULCRUM-VT Study reported a 97.4% acute success rate for Ultralow Temperature Cryoablation (ULTC) in treating Sustained Monomorphic Ventricular Tachycardia (SMVT) among 207 patients, with a 2.5% rate of major adverse events.

Future Implications: The promising preliminary results suggest that ULTC could transform treatment for ventricular tachycardia, with long-term outcomes and further effectiveness analysis expected to be shared at future conferences.

Leadership Change at Adagio Medical: Deborah Kaster has been appointed as Chief Financial Officer in addition to her role as Chief Business Officer, effective September 5, 2025, succeeding Dan George.

Kaster's Background: Kaster joined Adagio Medical in March 2025 and has extensive experience in investor relations and business development, having previously worked at Shockwave Medical, Gilmartin Group, and Kyphon.

Penny Stocks to Watch: Adagio Medical, China SXT Pharmaceuticals, and Motorsport Games are highlighted as penny stocks to monitor on April 22, 2025, based on their high Dollar Volume despite recent stock price declines.

Company Highlights: Adagio Medical focuses on cardiac arrhythmia treatments and received FDA recognition; China SXT Pharmaceuticals faced a significant drop amid market issues; Motorsport Games regained Nasdaq compliance but also saw a stock price decrease.

Adagio Medical Holdings Inc Update: Shares of Adagio Medical surged by 124% to $2.07 after the FDA granted Breakthrough Device Designation for their vCLAS cryoablation system, which targets drug-resistant ventricular tachycardia in patients with heart disease.

Market Participation Information: Investors interested in buying shares of Adagio can do so through brokerage accounts, with options available for purchasing fractional shares or shorting the stock, while the company continues its investigational trials in the U.S. and has already received approval in Europe.